Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study

J Eur Acad Dermatol Venereol. 2020 Dec;34(12):e803-e805. doi: 10.1111/jdv.16648. Epub 2020 Aug 3.

Authors

M A Menter¹, G J Murakawa², H Glover³, A M Mendelsohn⁴, J Parno⁴, S J Rozzo⁴, D Davidson⁴, A K Gupta^{5

6}

Affiliations

¹ Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX, USA.
² Somerset Skin Centre, Troy, MI, USA.
³ Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA.
⁴ Sun Pharmaceutical Industries, Inc, Princeton, NJ, USA.
⁵ Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, ON, Canada.
⁶ Mediprobe Research, Inc, London, ON, Canada.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Psoriasis* / drug therapy
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab

Grants and funding